Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Gastrointestinal 1

Conditions

Turcot syndrome 1Rectal Neoplasms 1Neoplasms 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 7Radiotherapy 6Radiosurgery 4pembrolizumab 3Specimen Handling 3Paclitaxel 3Fluorodeoxyglucose F18 3Carboplatin 3sargramostim 2cediranib 2Thiotepa 2Radiation 2Nivolumab 2Melphalan 2IFL protocol 2Granulocyte Colony-Stimulating Factor 2Genetic Testing 2Gemcitabine 2FAPI-46 2Busulfan 2130-nm albumin-bound paclitaxel 2tipifarnib 1sodium thiosulfate 1regorafenib 1paclitaxel-Angiopep-2 conjugate 1montelukast 1etoposide phosphate 1entrectinib 1entinostat 1clevudine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × Diffusion Tensor Imaging × Gastrointestinal × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡